On Tuesday, November 10, Precision Biosciences released their Q3 2020 financial results and business update (press release), highlighting their allogeneic CD19 CAR-T PBCAR0191. Of note, management anticipate in Q4 2020 to present updated PBCAR0191 Ph1/2a data in a company-sponsored event. Furthermore, Precision provided guidance on their clinical development agreement evaluating PBCAR269A (allogeneic BCMA CAR-T) with nirogacestat (gamma-secretase inhibitor). Below, Celltelligence provides insights into Precision and Servier’s expanded agreement targeting solid tumors, pipeline updates, and upcoming data from their allogeneic CD19 CAR-T PBCAR0191.
About The Author
The Celltelligence Team
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
Sign UpFREE
You’ll be able to access the full article from your Celltelligence Library after signing up.
If you receive our email blasts, you already have an account. Log in now
Context counts when making decisions.
Sign UpFREE
You’ll be able to access the full article from your Celltelligence Library after signing up.